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Summary 
The nature of alloantigens seen by T lymphocytes, in particular the role of  peptides in allorecognition, 
has been studied intensively whereas knowledge about the in vivo emergence, diversity, and the 
structural basis of specificity of alloreactive T  cells is very limited. Here we describe human T 
cell clones that recognize HLA-B35 alloantigens in a peptide-dependent manner. TCR sequence 
analysis revealed that several of these allospecific clones utilize homologous TCR: they all express 
TCRAV2S3J36C1  and TCRBV4S1J2S7C2  chains with highly related CDR3  sequences.  Thus 
peptide-specific alloreactivity is reflected in homologous CDR3  sequences in a manner similar 
to that described for T cells that recognize nominal peptide/self-MHC complexes. The in vivo 
frequency of this TCR specificity was studied in unstimulated PBL of the responding cell donor 
who was not sensitized against HLA-B35. The vast majority (,'o75%)  of the VA2S3J36 junctional 
regions obtained from two samples  of PBL, isolated at a 9-yr interval, encode CDR3 identical 
or homologous to those of the functionally characterized HLA-B35 allospecific T cells. These 
data are most easily explained by a model of alloreactivity in which persistent or recurrent exposure 
to a foreign peptide/self-MHC complex led to the in vivo expansion and long-term maintenance 
of specific T  cells that show fortuitous crossrecognition of an HLA-B35/peptide  complex and 
dominate the alloresponse against HLA-B35. 
T  cell recognition is confined to peptide stretches of anti- 
genic proteins that are selected by binding to polymorphic 
peptide-binding grooves of MHC class I and class II mole- 
cules (1-3). Positive and negative selection steps in the thymus 
prepare T  cells for this task (4).  Self peptides presented by 
autologous MHC molecules play an essential role in both 
selection steps (5). Against this background T cell-mediated 
alloreactivity remains puzzling since it does not concur with 
the rules of positive and negative selection: aUoreactive T cells 
respond to MHC molecules for which they have not been 
positively selected. Likewise they are not negatively selected 
against self peptides presented by allogeneic molecules (sub- 
sequently referred to as "allo-self complexes"), rather they 
are specifically reactive for such allo-self complexes (6,  7). 
Characterization of T cell clones specific for foreign peptide 
presented by self MHC and MHC alloantigens demonstrated 
that alloreactivity is not a function of a particular population 
of T  cells but is an intrinsic property of many T  cells (8, 
9) and that this dual specificity is accomplished by one TCR 
(10).  It is assumed that alloreactivity represents fortuitous 
cross-reactive binding of TCR to particular allo-self complexes 
but the molecular basis of this cross-reactivity is not yet fully 
understood (11, 12). 
Insight into the structural basis  of alloresponses  can be 
gained by analyzing TCR of alloreactive T  cells.  A  three- 
dimensional model of the TCR proposes that  CDR1  and 
2, encoded by TCRAV and TCRBV gene segments, interact 
with the c~-helices of the MHC molecules and the hypervari- 
able CDR3, encoded by V-(D)-Jjunctional regions, contact 
protruded peptide side chains (13).  Analyses of alloreactive 
T cells in mice and humans revealed a complex TCR usage 
and support the hypothesis that an alloresponse is mediated 
by heterogeneous T cells recognizing a wide variety of allo- 
self complexes (14-17). 
In contrast, we show here that a group of HLA-B35 specific, 
peptide-dependent, alloreactive T  cells utilize a set of dis- 
tinct, yet nearly identical TCR. One of these TCR sequences 
was found to be predominantly expressed in the unstimu- 
lated PBL of the donor whose cells were stimulated in vitro 
to generate the alloreactive T  cells.  Furthermore, a second 
of these TCR sequences was detected with high frequency 
in a PBL sample obtained from this donor nine years later. 
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an  allo-self complex  is  recognized  presumably  due  to  its 
similarity to a nominal peptide/self-MHC complex that selec- 
tively activated and maintained these T  cells in vivo over a 
very long time. 
Materials and Methods 
Cells.  PBL ofheahhy Caucasian donors were HLA typed using 
local and  International Histocompatibility Workshop  reagents. 
HLA-B35 variants were characterized by DNA sequencing (18). 
EBV-transformed lyrnphoblastoid  cell lines (LCL) 1 were established 
using culture supernatants of the marmoset cell line producing the 
B95.8 strain of EBV (American Type Culture Collection, Rock- 
ville, MD). LCL or PHA-stimulated PBL were used as target cells 
for the ceil-mediated lympholysis assay and their complete HLA 
types are as follows: 
GM: A2,B8,B40,Cw7,DK2,DR3; 
DS: A2,A3,B* 3501,B37,Cw4,Cw6,DR1,DR2; 
PR: A1,A3,B* 3501,Cw4,DR4,DR13 
HF: A1,A3,B" 3503,B38,Cw4,Cw6,DR3,DK13; 
TL: A2,A24,B13,B*3508,Cw4,Cw6,DK3,DR7; 
GN: A3,A31,B*3508,B55,Cw3,Cw4,DR4. 
The HLA-B'3501 gene was isolated from a genomic library of donor 
DS. The HLA-A, -B, -C null I_CL 721.221 (19) was obtained from 
the ATCC and transfected by electroporation with HLA-B*3501 
cloned into the pHEBo vector (20). P815-HTR mastocytoma cells 
were also transfected with HLA-B*3501 as described elsewhere (21). 
T2 is a fusion product of the T-LCL CEM and the LCL721.174 
and is MHC hemizygous (22). The residual class I region encodes 
HLA-A2, -Cwl, -B51; the class II region has a large deletion in- 
cluding the TAP and LMP genes (23). Untransfected T2 cells were 
kindly provided by Dr. R. Tampe (Max-Planck Institute of Bio- 
chemistry, Martinsried, Germany); T2 cells transfected with HLA- 
B'3501 were kindly provided by Dr. M. Takiguchi (Institute of 
Medical Science, Tokyo, Japan). The cell lines BM28.7 and BM36.1 
were generously provided by Dr.  A.  Ziegler  (Institute  of Ex- 
perimental Oncology and Transplantation, Berlin, Germany); they 
were derived by mutagenesis from the Burkitt's lymphoma line 
BJAB; BM28.7 is MHC hemizygous and carries only the A1, Cw4, 
B*3501 haplotype of BJAB. BM36.1 carries a deletion in its TAP2 
gene and lacks  a functional peptide transporter (24). 
CTL.  An FILA-B35-specific CTL line was made by stimulating 
B35-negative PBL of donor GM, isolated in 1979, with irradiated 
B*3501-positive lymphocytes of donor DS for 6 d in MI.C. After 
positive selection of CD8 §  lymphocytes using anti-CD8-anti- 
body-coated magnetic beads (Dynal, Hamburg, Germany), cloning 
was performed by seeding 0.3 cells/well in the presence of rlL-2 
(40 U/ml) (Proleukin; Eurocetus, Frankfurt, Germany) and irradi- 
ated stimulator cells. The remaining CD8 + lymphocytes were cul- 
tivated for several months with irradiated stimulator cells (DS) and 
rlL-2 (40 U/ml). From this CD8 § line Vc~2.3-bearing T cells were 
positively selected implementing mAb F1 (T Cell Sciences, Cam- 
bridge, MA) in combination with goat anti-mouse IgG antibodies 
coupled to magnetic beads (M450; Dynal). 
i Abbreviations used in this paper: I.CL, lymphoblastoid cell lines; MFI, 
mean fluorescence  intensity. 
Cell-mediated Lympholysis Assay.  Cytotoxic activity was deter- 
mined using a standard  chromium release assay (25).  A percent 
cytotoxicity was  calculated  using the formula:  %  lysis  =  ([ex- 
perimental cpm  -  spontaneous cpm]/[total cpm -  spontaneous 
cpm])  xl00. 
lmmunofluorescence Analysis and Antibodies.  Indirect immuno- 
fluorescence was made using undiluted hybridoma culture super- 
natants  or ascites  (1:1,000)  in the first step followed by FITC- 
conjugated goat anti-mouse Ig antibody (F261; Dakopatts, Copen- 
hagen, Denmark). The following antibodies were used: anti-Bw6 
(Biotest, Dreieich, Germany) for assessment  of HLA-B35; F1 (T 
Cell Sciences) for detection of Vc~2.3  § T cells; and MPC 11 and 
UPC 10 (Sigma Chemical Co., St. Louis, MO) as isotype controls. 
For two-color immunofluorescence cells were incubated with un- 
labeled primary antibody, washed twice, and stained with PE-labeled 
rabbit anti-mouse Ig F(ab')2 (Medac, Hamburg, Germany). Free 
sites were saturated with excess mouse IgG1 and lgG2a (Coulter, 
Hialeah, FL). Finally the cells were incubated with FITC-conjugated 
anti-CD8 mAb (Immunotech, Marseille,  France).  Analyses were 
carried out on a FACScan  |  instrument (Becton Dickinson, Moun- 
tain View, CA) with gates  set to include only living cells. 
Analysis of TCR Usage  and Determination of TCR Sequences.  Total 
cellular RNA was isolated using RNAzol B (CINNA/BIOTECX, 
Houston, TX). TCRA and TCRB cDNA of the T cell clones was 
synthesized using the oligonucleotides Cae and Cfle (26) and of 
the PBL, the T ceil line and the Va2.3 selected T cells using the 
oligonucleotides CccST (5' CACTGAAGATCCATCATCTG 3') and 
C~ST (5' TAGAGGATGGTGGCAGACAG 3') with RAV-2 reverse 
transcriptase (Amersham Buchler GmbH, Braunschweig, Germany). 
For the T cell clones PCK was performed from cDNA with five 
sets of TCRAV (Vul-6/7-12/13-16,23,24/17-22/25-29,32)  and four 
sets of TCRBV family specific oligonucleotides (V~l-4, 5.1,5.2,6/7- 
12/13.1,13.2,14-18/19-24)  in combination with biotinylated oligo- 
nucleotides derived from TCRAC (T-Cc~) (27) and TCRBC (3'C3) 
(28) gene segments, respectively. Oligonucleotides V~I to V~12 
with Vcd7 to 21 and V/~I to V320 were synthesized according 
to published sequences (27, 28) and supplemented with the fol- 
lowing oligonucleotides: 
V(~13: 5' GAGCCAATTCCACGCTGCG 3' 
Vcd4:  5' CAGTCTCAACCAGAGATGTC 3' 
Veal5:  5' GATGTGGAGCAGAGTCTTTTC 3' 
V~16:  5' TCAGCGGAAGATCAGGTCAAC 3' 
V~22:  5' TACACAGCCACAGGATACCCTTCC 3' 
V(x23: 5' TGACACAGATTCCTGCAGCTC 3' 
V~24:  5' GGAGGGAAAGAACTGCACTCTT 3' 
Vc~25: 5' ATCAGAGTCCTCAATCTATGTTTA 3' 
Ver  5' AGAGGGAAAGAATCTCACCATAA 3' 
V~27:  5' ACCCTCTGTTCCTGAGCATG 3' 
Vot28:  5' CAAAGCCCTCTATCTCTGGTT 3' 
Vot29:  5' AGGGGAAGATGCTGTCACCA 3' 
Vot32:  5' TGCAAATTCCTCAGTACCAGCA 3' 
V321:  5' AAAGGAGTAGACTCCACTCTC 3' 
V322:  5' CATCTCTAATCACTTATACT 3' 
V323:  5' TATCCCTAGACACGACACTG 3' 
V324:  5' GACTTTGAACCATAACGTACA 3' 
PCR was performed starting with 2 min at 940C, then 30 cycles 
of 30 s at 95~  30 s at 56~  and 60 s at 72~  finishing with 
5 min at 72~  Amplification in a 50-/xl volume used 2 U  Taq 
polymerase (Pharmacia, Freiburg, Germany) and a Omnigene ther- 
mocycler (Hybaid, Teddington, UK) under tube control. DNA 
strands were separated using streptavidin-coupled  magnetic patti- 
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formed with Sequenase  2.0  (Un.  States Biochem.  Corp.,  Cleve- 
land,  OH)  and  [32p]dATP or using  the A.L.F.  DNA  sequencer 
(Pharmacia) with the AutoRead sequencing kit (Pharmacia) and 
fluorescein-labeled  primers. The repertoire of the T  cell line was 
analyzed for expression of 30 TCRAV and 24 TCRBV gene fami- 
lies in separate PCR. To obtain semiquantitative estimates of gene 
usage and to monitor e~ciency of amplification, primer pairs en- 
compassing a stretch of the TCRAC and TCRBC gene segments, 
respectively,  were included  as internal  controls  in  each reaction 
(5' Ccr  for TCRA-PCR and 5' C~-ST/3'C/8-ST for 
TCRB-PCR). 
P-5'c~ST: 5' CTGTGCTAGACATGAGGTCT 3' 
P-3'olST:  5' CCTGCCTCTGCCGTGAATGT 3' 
P-5'/3ST: 5' AAGCAGAGATCTCCCACAC 3' 
P-3'~ST." 5' GAGGTAAAGCCACAGTTGCT 3' 
The PCK protocol was as above except that 35 cycles were per- 
formed: Amplification products were separated on a 4% NuSieve 
3:1 agarose gel (FMC Corp. BioProducts, Rockland, ME) and pho- 
tographed (Film Type 55; Polaroid, Cambridge, MA). The TCRAV 
and TCRBV amplicons of the T cell line were directly sequenced 
as described above. 
Sequencing of TCR Junctional Regions  from PBL.  The cDNA 
prepared from unstimulated PBL samples of donor GM was ampli- 
fied with oligonucleotides  Va2.3 and Jc~36 to isolate TCRAV2S3J36 
junctional  regions  and  oligonucleotides  VB4-Sal  and J~2.7  for 
TCRBV4J2S7 junctional  regions. 
Vc~2.3: 5' TGTTCTAGAGGGAGCCACTGTCG 3' 
Jc~36: 5' GGGAATTCGGGAATAACGGTGAGTCTC 3' 
VB4-Sal:  5' CCGTCGACATATGAGAGTGGATTTGTC 3' 
J/32.7:  5' CCGAATTCTTTTTCAGGTCCTCTGTG 3' 
Both PCR were optimized for specific amplification via primer se- 
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Figure  1.  Cytotoxic activity of al- 
loreactive  T cells  against  TAP-deficient 
mutant cells. The T cell clones, the 
T cell line A.1-CDS, and the TCR- 
Vot2.3-positive  cells  selected  from this 
line were tested for lysis of cell lines 
T2, T2-B*3501, BM36.1 and its func- 
tional TAP-expressing  precursor cell 
line BM28.7. Data  are given as % 
lysis, calculated according to the for- 
muh given in Materials and Methods. 
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started with 2 min at 94~  then 35 cycles of 30 s at 95~  30 
s at 62~  (V~2.3), and 58~  (VB4), respectively; 60 s at 72~ 
finishing with 5 min at 72~  Amplification in a 50-#1 volume 
used 2 U Taq polymerase. VA2S3J36 amplicons were cloned into 
pUC18 via XbaI and EcoRI and VB4J2S7 amplicons via SalI and 
EcoRI restriction  sites built into  the PCK primers. The cloned 
junctional regions were sequenced with an A.L.F. DNA sequencer 
using  the fluorescein-labeled reverse primer. 
Results 
Peptide-dewndency  of HLA-B35-specifig Alloreactive T Cells. 
The serological specificity HLA-B35 encompasses at least eight 
different alleles  (29).  Previously, we described several B35- 
specific,  alloreactive T  cell clones derived from donor GM 
that exhibited different lysis patterns for target cells expressing 
molecular subtypes of HLA-B35 (18).  An additional T  cell 
clone (clone F) not initially characterized is included here. 
LCL of B'3501 donors were well recognized by all clones, 
recognition of LCL ofB'3508 donors varied among the clones 
and none of the clones lysed LCL of a B'3503  donor  (18 
and data not shown). B'3503 and B'3508 differ from B'3501 
by single amino acid substitutions at positions thought  to 
interact with the peptide but not to be accessible to a TCR 
(18). The differences in allorecognition of cells expressing B35 
variants suggested that the T cells were specific for particular 
B35 allo-self complexes. Recognition of EBV peptides could 
be excluded since all clones lysed activated T  cells of donor 
DS with equal efficiency (data not shown).  All clones also 
lysed the HLA-A, -B, -C null cell line LCL721.221 after trans- 
fection with HLA-B*3501, but not untransfected LCL721.221 
cells,  nor did they lyse murine  P815 cells  transfected with 
HLA-B*3501 (30). These results confirmed that HLA-B*3501 
molecules played a direct role in determining the specificity 
of the T cells; the difference with human versus mouse trans- 
fectants expressing HLA-B35 suggested that  species  varia- 
tions in endogenous peptides might influence allorecognition. 
To  substantiate  the  assumption  that  these T  cells  were 
peptide-dependent  we  studied  their  lysis  of two  different 
B'3501 positive target cells having defects in the transport 
of endogenous peptides (Fig. 1). BM36.1 cells are TAP2 mu- 
tant derivatives of BM28.7 whose surface expression of en- 
A 
clone A 
clone B 
clone C 
clone D 
clone E 
Y  F  C  A  Y  R  S  T  E  T  S  Y  D  K  V  I  F 
TATTTCTGTGCT  TATAGGAGCACGG  AAACC TCC TACGACAAGGTGATAT T T 
AV14S1  A  J50 
Y  L  C  V  V  I  R  T  G  A  N  N  L  F  F 
TACCTCTGTGTGGTGA  TACG  AAC TGGGGCAAACAACCTC T TCTT T 
AV2S3  A  J36 
Y  F  C  A  L  I  P  S  G  N  T  P  L  V  F 
TACTTCTGTGCTCTGA  TTCC  TTCAGGAAACACACC TC T TGTC T T T 
AV12S1  A  J29 
Y  L  C  V  V  I  K  A  G  A  N  N  L  F  F 
TACCTCTGTGTGGTGA  TCAAGG  CTGGGGCAAACAACC TC T TC T T T 
AV2S3  AJ36 
Y  L  C  A  V  S  N  G  W  N  N  N  D  M  R  F 
TACCTCTGTGCTGTG  AGTAACGGATGG  AATAACAATGACATGCGC T T T 
AV23S1  AJ43 
clone F  Y  F  C  A  P  S  G  T  Y  K  Y  I  F 
TACTTCTGTGC  TC  CC TCAGGAACC TACAAATACATCT T T 
AV8S1  AJ40 
~1~:D8  Y  L  C  V  V  I  K  T  G  A  N  N  L  F  F 
TACCTCTGTGTGGTGA  TTA  AAACTGGGGCAAACAACC TC T TC T T T 
AV2S3  A  J36 
Y  L  C  A  L  V 
TACCTCTGTGCTCTAG  TG~] 
AV5S1 
GGTGGTACTAGC TATGGAAAGC TGACAT T T 
A  J52 
Y  L  C  A  V  R  G  P  P  G  A  G  S  Y  Q  L  T  F 
TACCTCTGTGCTGTGAG  GGGACCTC  C TGGGGCTGGG~,GT TACCAAC TCAC T T TC 
AV7S2  AJ28 
Y  F  C  A  L  S  G  L  G  G  Y  Q  K  V  T  F 
TACTTCTGTGCTCTGAGT  GGGCTC  GGGGG T TACCAGAAAGT TACCT T T 
AV12S1  A  J13 
Y  F  C  A  Y  W  G  A  Y  N  F  N  K  F  Y  F 
TACTTCTGTGCG  TACTGGGGGGCA  TACAACT TCAACAAATTTTACTT  T 
AV32S1  A  J21 
506  In Vivo Expansion  of Alloreactive T  Cells by an Antigenic Mimic dogenous HLA-B*3501 molecules is reduced 10-fold (24 and 
data not shown). All T cell clones lysed BM28.7 cells at levels 
similar to B'3501 cells of donor DS; whereas BM36.1 cells 
were not recognized,  except by clone F that showed weak 
lysis compared to BM28.7 cells. T2 cells have no TAP1 and 
2 genes and consequently their peptide transport is heavily 
impaired (22). The endogenous HLA-A2 molecules of T2 
are expressed at 20-25% of wild-type level (31); expression 
of other HLA-class I molecules, such as endogenous HLA- 
B51, was barely detected (32). T2 cells transfected  with B'3501 
DNA bound an anti-Bw6 antibody showing that they ex- 
pressed B'3501 molecules (T2: negative control [mean fluores- 
cence intensity (MFI)  =  127], anti-Bw6 [MFI  =  208]; T2- 
B'3501: negative control [MFI  =  190], anti-Bw6 [MFI  = 
341]). Untransfected T2 cells as well as T2-B*3501 transfec- 
tants  were poorly recognized by all CTL (Fig. 1). 
After several months of culture the CD8 + T cell fraction 
from which the T cell clones were derived exhibited a pat- 
tern of lysis similar to those of clones B, C, and D: it lysed 
721.221  cells transfected  with  HLA-B*3501,  recognized 
B'3501 and B'3508, but not B'3503 cells (not shown), and 
hardly recognized the B'3501 transporter-defective cell lines 
(Fig. 1). These data supported the conclusion that the clones 
as well as this line were B35 specific and peptide dependent. 
TCR  Sequences of HLA-B35  Alloreactive T  Cells.  The 
TCRct and TCRfl variable regions of the alloreactive T cell 
clones were sequenced after PCK amplification using family- 
specific oligonucleotides  (Fig. 2, A  and B).  Interestingly, 
clones B and D utilized nearly identical TCK: both had recom- 
bined TCRAV2S3 with TCRAJ36  and TCKBV4S1 with 
TCRBJ2S7  gene segments. The CDR3 sequences of both 
TCR chains were also strikingly similar; they were of iden- 
tical overall length and composed of the same or chemically 
related amino acids located at the same positions  (Fig. 3). 
The other four T  cell clones used  different  TCRAV and 
TCRAJ gene segments. Clones A and C expressed TCR~ 
chains  encoded from TCRBV7  gene  segments  that  had 
CDR3B regions of identical length with homologous car- 
boxyterminal halves. Five  of the  six  clones  used  either 
TCRBJ2S3  or TCRBJ2S7  gene segments  that are closely 
B 
clone A 
clone B 
clone C 
clone D 
clone E 
clone F 
AA-CD8 
C  A  S  S  Q  E  W  L  G  Q  G  I  S  D  T  Q  Y  F 
TGCGCCAGCAGCCAAG  AGTGGT TGGGACAGGGCA'r  T TCG  GATACGCAGTATTTT 
BV7S1  BD1  BJ2S3 
C  S  V  E  G  G  V  F  Y  E  Q  Y  F 
TGCAGCGTTGAA  GGCGGGGTCTT  CTACGAGCAGTACT TC 
BV4S1  BD2  BJ2S7 
C  A  S  S  Q  A  L  P  L  P  G  M  T  Y  E  Q  Y  F 
TGTGCCAGCAGCCAAG  C TCTCCCGT  TACCGGGAATGA  CCTACGAGCAGTACTTC 
BV~S2  BD2  BJ2S7 
C  S  V  E  G  G  T  I  Y  E  Q  Y  F 
TGCAGCGT TGAA  GGGGGGACGAT  CTACGAGCAGTACTTC 
BV4S1  BD1/BD2  BJ2S7 
C  A  S  S  Y  Q  T  V  T  D  T  Q  Y  F 
TGTGCCAGCAGT  TACCAGACAGT  CACAGATACGCAGTATTTT 
BV13S2  BD1  BJ2S3 
C  A  S  S  E  I  L  Q  G  N  E  K  L  F  F 
TGTGCCAGCAGT  GAAATCCTCCAGGG  TAATGAAAAACTGTTTTTT 
BV22S1  BD1  BJIS4 
C  S  V  E  G  G  S  T  Y  E  Q  Y  F 
TGCAGCGTTGAA  GGGGGGTCTA  CCTACGAGCAGTACTTC 
BV4S1  BD1  BJ2S7 
C  A  S  S  L  Y  I  R  V  P  Y  E  Q  Y  F 
TGTGCCAGCAGCTTA  TATATCAGGGTGC  CCTACGAGCAGTACTTC 
BV6S2  BD1  BJ2S7 
C  A  S  S  T  A  G  G  T  Y  E  Q  Y  F 
TGTGCCAGCAGCA  CCGCAGGGGGCA  CCTACGAGCAGTACTTC 
BV13S1  BD1  BJ2S7 
C  A  S  S  Q  D  R  G  T  E  A  F  F 
TGTGCCAGCAGCCAA  GACAGGGG  CAC TGAAGC T T TCT'IT  T 
BV16S1  BD1  BJIS1 
C  A  T  S  S  D  R  G  R  N  Q  P  Q  H  F 
TGTGCCACCAGCAGC  GACAGGGGGC  GCAATCAGCCCCAGCATTTT 
BV24S1  BD1  BJIS5 
Figure  2.  Sequences  of  the 
TCRA (A) and TCRB (B)junc- 
tional regions of the T cell clones 
A-F  and  the  five  TCRA  and 
TCRB amplicons obtained from 
the  T  cell  line.  Amino  acid 
residues  are  indicated  with  the 
single letter code. Since the germ- 
line  sequences  for  most  of the 
TCRAV and TCRBV gene seg- 
ments are unknown their borders 
are inferred by comparison  with 
other published cDNA sequences. 
The BV7S2 gene segment used by 
clone C differs from the published 
sequence BV7S2 (clone PL4.19) by 
a silent C to T substitution in the 
codon  for  the carboxy-terminal 
cysteine. Nucleotide stretches cor- 
responding  to  TCRBD1  and 
TCRBD2  sequences  are  under- 
lined. Boxed nudeotides indicate 
a frameshift  at the N/J junction 
leading  to an out of" frame tran- 
script.  These  sequence  data  are 
available from EMBL/GenBank/ 
DDBJ under accession numbers 
Z46961 (A) and Z46963  (B). 
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B 
AV2S3  N 
A.1-CD8 +  L  C  V  V  I  K 
PBL seq. 1 
cloneD  L  C  V  V  I  K  A 
PBL seq. 2 
cloneB  L  C  V  V  I  R 
PBLseq. 3  L  C  V  V  I  R  T 
PBL~tq. 4  L  C  V  V  T  R 
PBLseq. 5  L  C  V  V  I  V  R  G 
(Fig. 4 D), demonstrating that they coexpressed V34 receptor 
chains. 
An36  Further TCRA sequences detected in the unselected line 
T G A n  N t  F  F  o  were an out of frame V5SIJ52C1 transcript,  a V7S2J28 se- 
quence with a CDR3 homologous to VA2S3J36  sequences 
G A N ,  t  F  F  G  (i.e.,  an aliphatic residue, followed by a basic aliphatic res- 
idue, followed by three small nonpolar residues), a sequence 
v O A N N L F  F  G  using V12S1 like clone C, and a V32S1J21C1 sequence (Fig. 2 
A). Additional  TCRB sequences were defined as V6S2J2S7C2, 
G  A  N  N  L  F  F  O  V13S1J2S7C2, V16S1J1S1C1,  and V24S1JIS5C1 (Fig.  2 B). 
Three of five TCRB  sequences characterized in  the T  cell 
T  G  A  N  N  L  F  F  G  line used the J2S7 gene segment which is also present in three 
T cell clones. The VB16S1 and VB24S1 sequences exhibited 
T G A N N L F F G  a unique, common CDR3 that shared the amino acid sequence 
"DRG"  at  the  same  position  exclusively encoded by the 
TCRBD1 gene segment.  In both cases BD1 was joined to 
the TCRBV and TCRBJ gene segments without insertion 
ea~s7  of additional  nucleotides,  thus representing  so-called fetal- 
v  E O  v  F G PG  type TCR (33). 
In Vivo Expansion of  HLA-B35 Alloreactive T Cells.  TCIk 
Y  E  O  Y  F  G  P  G  with rearranged  VA2S3J36  and VB4S2J2S7 gene segments 
and highly related CDR3 were found in three of seven HLA- 
v  E  o  v  F  G  P  G  B35-specific, alloreactive T cells and one of these was preva- 
lent in the unselected line.  To understand  how preferential 
receptor usage arose following allogeneic stimulation we ana- 
lyzed the diversity of VA2S3J36 TCR in the 1979 PBL sample 
of donor GM that was used for establishing the alloreactive 
T  cells  and  in  a PBL  sample from  1988.  Two  color im- 
munofluorescence of the PBL samples revealed  that 3.4 and 
2.0%  of the  CD8 + cells expressed Va2.3  TCRa  chains, 
respectively (Fig. 4, E and F). Frequencies of 2-6% were de- 
scribed for VoL2.3/CD8 + T cells in PBL of healthy individ- 
uals (34). For analysis  of the VA2S3J36  TCR repertoire we 
designed a PCR specific for VA2S3J36 rearranged TCR. Single 
strand chain polymorphism analysis of the PCR products of 
the two GM samples showed strong distinct bands whereas 
those of seven other unrelated individuals gave weak bands 
or smears,  as expected for heterogeneous mixtures of TCR 
having different CDR3 (data not shown). The strong bands 
of the GM samples indicated a clonal expansion of VA2S3J36 
TCR-expressing T cells; therefore "50 cloned VAS3J36 junc- 
tional regions were sequenced from each PBL sample.  In the 
1979 isolate a single sequence identical to the junctional se- 
quence  of the  CD8 +  line  was  found  in  the  majority  of 
clones (32 of 55) (Fig.  5). Sequence 2 is identical to that of 
clone D. No PCR clone was found with the junctional se- 
quence of T cell clone B; however one PCR clone identical 
in amino acid sequence but differing by five nucleotides in 
the junctional  region was found twice (sequence 3).  Four 
additional  sequences  encoded  identical  or  highly  related 
CDR3. Since two of them differed from sequence I by only 
one nucleotide they may represent Taq incorporation  error 
variants. Altogether 41 of 55 junctional sequences (75%) could 
be grouped into  one homology class. 
In the second PBL sample, 27 of the 50 clones (54%) had 
junctional regions identical to clone D  (Fig.  5). Sequence 1, 
which was dominant in the 1979 sample was found six times 
(12%).  Again,  the junctional sequence of clone B was not 
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BV4S1  NDN 
A.1-CD8 §  C  S  V  E  G  G  $  T 
cloneD  C  S  V  E  G  G  T  I 
cloneB  C  S  V  E  G  G  V  F 
Figure 3.  Comparison of the homologous CDR3 sequences of the 
TCILAV2S3J36C1 (A) and TCRBV4S1J2STC2  junctional regions (B) 
characterized in the allostimulated T cell  clones and line and the unstimu- 
lated PBL for donor GM. 
related in sequence.  In addition we found an out of frame 
rearranged TCRBV2JS3C1 for clone D, TCtLAV17J40C1 for 
clone E,  and TCRBVIJ2S4C2  for clone F. 
TCR Usage and Sequences of  the HLA-B3 5-specifiG Alloreac- 
rive T  Cell Line.  We also evaluated the TCtL usage of the 
CD8+-positive T  cell line that was initiated from the same 
primary MLC as the clones. Repertoire analysis detected five 
TCRAV (data not shown) and five TCRBV gene segments 
(Fig. 4 C), revealing the oligoclonal composition of the line. 
Direct sequencing of each amplicon resulted in a single, dearly 
readable sequence even in the V(D)J junctional region (Fig. 
2, A  and B), thus the vast majority of sequences comprising 
each amplicon was derived from a clonal TCR. The T  cell 
line also included TCR composed of VA2S3J36 and VB4S1J2S7 
rearrangements like those identified in clones B and D. The 
CDR3 sequences of each receptor chain exhibited close ho- 
mology, in terms of length and amino acid composition, to 
CDR3 ofdones B and D  (Fig. 3). Therefore it seemed likely 
that the Va2.3 and V34.1 chains were expressed by the same 
T  cell population.  To demonstrate this directly we isolated 
Vo~2.3-bearing T  cells from the line via immunomagnetic 
bead separation. FACScan analysis revealed that 33% of un- 
selected cells bound the Va2.3-specific mAb (Fig. 4 A); 98% 
of the positively selected cells were Vc~2.3 positive (Fig.  4 
B). When tested in CML these T cells showed a lysis pattern 
like the unseparated line and clones B and D (Fig. I and data 
not shown). PCIk analysis of cDNA prepared from the selected 
Vo~2.3 § T  cells showed that  only amplicons for TCRAV2 
(data not shown) and TCRBV4 were visible after 35 cycles 
508 Figure  4.  TCILV gene seg- 
ment  expression  of  the T cell  line 
A.I=CD8. FACScan  |  analysis of 
the A.1-CD8 line (A) and the 
TCR-V~2.3 positively selected 
cells of this line (B)  with the 
Vot2.3 specific  mAb F1 (hatched 
line,  isotype control). TCRBV 
repertoire (C) of the T cell line 
A.1-CD8 determined with  26 
TCRBV family-specific  primers 
and coamplification  of  TCRBC as 
an internal  control.  Analysis  of the 
TCR-V~2.3 positively selected 
cells for the TCRBV gene seg- 
ments detected in the line (D). 
Frequency of TCR Voe2.3/CD8 
positive cells in PBL samples of 
donor GM from 1979 (E)  and 
1988  (F). The  Vc~2.3-specific 
mAb F1 was indirectly labeled 
with PE and used  in combination 
with the FITC  labeled  anti-CD8 
mAb. The percentages  of  cells are 
indicated in each quadrant. 
found but a TCR identical in amino acid but differing in 
nucleotide sequence  (sequence  3)  was  detected five times 
(10%). Therefore after nine years the repertoire of VA2S3J36 
TCR was still dominated by a particular homology class that 
represented 76% (38 of 50 clones) of the  junctional sequences. 
Junctional sequences not belonging to this homology  group 
(sequences 6-23) were diverse in length and amino acid com- 
position. None was found more than three times or in both 
PBL samples. 10 started with codon AAC encoding asparagine 
(but none with AAT that also encodes asparagine) indicating 
that the AAC codon represented the 3' end of the germline 
TCKAV2S3 sequence, None of these sequences started with 
a codon for isoleucine, suggesting that the generation of the 
homologous sequences did not represent a frequent recom- 
binational event but that their dominance in the PBL of GM 
was due to selection through antigenic stimulation. 
Sequencing 50 cloned VB4S1J2S7junctional regions from 
each PBL sample supported the results of the VA2S3J36 reper- 
toire analysis. In the 1979 isolate we found the VB4SIJ2S7 
sequence of the T cell line once (Fig. 2 B); in the 1988 isolate 
the sequence of clone D was found four times. Both sequences 
correspond  to  the clonally expanded VA2S3J36 sequences 
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found at the two time points. The remaining VB4SIJ2S7 se- 
quences were neither identical nor homologous to those found 
in the alloreactive T cells (not shown). TCRBJ2S7 is utilized 
by 15-20%  of all TCRB sequences in peripheral blood (35) 
whereas TCRAJ36 is rearranged by •0.7%  of TCRA se- 
quences (36). Therefore the peripheral VB4SIJ2S7 repertoire 
probably encompasses  at least  10-fold more TCR than the 
VA2S3J36 repertoire. This could explain why we only found 
the TCRB sequence  corresponding to the expanded T  cell 
clone prevalent  at each time and that the TCRB sequences 
occurred at much lower frequencies than the TCRA sequences. 
Although several hundred clones would need to be sequenced 
to obtain an accurate frequency distribution in the VB4J2S7 
repertoire,  these initial findings are in agreement with the 
preferential expansion of the same T cells identified via their 
VA2S3J36 sequences. 
Discussion 
The currently favored model of alloreactivity suggests that 
peptides associated with allogeneic  MHC molecules play a 
critical role in dictating specificity (6, 7). Functional evidence sequence 1 
sequence la 
sequence lb 
sequence 2 
sequence 2a 
sequence 2b 
sequence 3 
sequence 4 
sequence 6 
sequence 6 
sequence 7 
sequence 7a 
sequence 8 
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sequence 10 
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sequence 14 
sequence 16 
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AAACTGGGGCAAACAACCTCTTCTTT 
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AAACTGGGGCAAACAACCTCTTCTTT 
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gAACTGGGGCAAACAACCTCTTCTTT 
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ACTGGGGCAAACAACCTCTTCTTT 
TGANNLFF 
AAACTGGGGCAAACAACCTCTTCTTT 
GANNLFF 
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GAsNLFF 
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N  N  L  F  F 
AAACAACCTCTTCTTT 
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TCAAACTGGGGCAAACAACCTCTTCTTT 
T  G  A  N  N  L  F  F 
ACTGGGGCAAACAACCTCTTCTTT 
Q  T  G  A  N  N  L  F  F 
TCAAACTGGGGCAAACAACCTGTTCTTT 
Q  T  G  A  N  N  L  F  F 
TCAAACTGGGGCAAACAACCTCTTCTTT 
CTGGGGCAAACAACCTCTTCTTT 
TCAAACTGGGGCAAACAACCTCTTCTTT 
n clones 
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Figure  5.  Junctional regions of 
cloned VA2S3J36 amplicons from 
unstimulated  PBL of donor GM 
from 1979 and 1988. Amino acid 
residues are shown as a single letter 
code. The asterisk (*) indicates a 
stop codon. Sequences  differing by 
single nucleotide substitutions  in 
TCRAV2S3 and TCRAJ36 gene 
segments are likely due to nucleo- 
tide  misincorporations  by  Taq 
polymerase (sequences 2a, 2b, and 
7a). Single nucleotide differences 
in the N region can be either due 
to Taq errors or actual junctional 
diversity  (sequences  la  and  b). 
Boxed  nucleotides  indicate  a 
frameshift  at  the  N/J junction 
leading to an out of frame tran- 
script.  These  sequence  data  are 
available from EMBL/GenBank/ 
DDBJ under  accession  number 
Z46962. 
supports the peptide-dependency of the HLA-B35-aUospecific 
T ceils studied here: first, 721.221 LCL transfected with B'3501 
were well lysed, whereas murine mastocytoma cells (P815- 
B'3501) were not recognized (30).  Secondly, these alloreac- 
tive T cells did not recognize two HLA-B*3501-expressing 
cell lines defective in TAP gene expression which fail to present 
the broad spectra of peptides found in normal cells. Thirdly, 
these clones distinguished ceils expressing allelic variants of 
B35 that differ by single amino acid exchanges located at po- 
sitions thought not to directly interact with the TCR but 
rather with bound peptide. Particularly the amino acid ex- 
change, Ser116 to Phe116, in the 3  pleated sheet of B'3503 
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on determining the carboxyterminal peptide anchor side chains 
(18). The sources of endogenous peptides recognized by the 
alloreactive T  cells in the context of HLA-B*3501  remain 
to be defined. Although they could be derived from viral pro- 
teins, several viruses of the Herpes family (EBV, CMV, HHV6, 
HHVT) that persist in lymphoid cells can be ruled out be- 
cause they show strong tropism for B or T lymphocytes and 
are normally harbored by very low numbers of lymphocytes. 
LCL and PHA-stimulated PBL were lysed at very high levels 
and purified CD4 or CD8 cells were also found to be well 
recognized in experiments not shown here. 
From mass spectrometry studies thousands of different pep- 
tides are known to associate with any MHC molecule (37); 
this extensive diversity would generate suitable ligands for 
many TCR and could account for the high frequency of al- 
loreactive T  cells. Several functional studies of murine and 
human alloresponses corroborate this model (6-9,  38-40). 
Less experimental data exists on TCR usage in alloresponses. 
Sequences of MHC class II specific, alloreactive T cell clones 
were found to be heterogeneous in usage of TCR V and J 
gene segments and in CDR3 sequence motifs and no simple 
correlation between sequence and  allospecificity could be 
drawn  (14-16).  One  study demonstrated biased usage of 
TCRBV elements and a nonrandom, but fairly heterogeneous 
composition of CDR3~ sequences for HLA-B27 specific, al- 
loreactive T cells; whereas TCRot chains exhibited no common 
features (17). This type of heterogeneity is expected if many 
different allo-self complexes induce allogeneic responses. 
Our TCR analysis of B35-allospecific T cell clones revealed 
a contrasting picture. Although usage of different V and J 
gene segments was detected in this  small set of cells,  two 
of six clones were found to express highly related receptors 
and a third highly related sequence was found as a dominant 
population in a long-term B35-allospecific  T cell line estab- 
lished from the same primary culture from which the T cell 
clones were derived. These results revealed  that a very re- 
stricted TCR usage can dominate an alloresponse.  This dom- 
inance could be explained either by a strong immunogenicity 
of the peptide/B35 ligand or by a selective in vivo expan- 
sion of these particular  T  cells.  Sequencing of VA2S3J36 
transcripts of the PBL sample used for generation of these 
B35 alloreactive T cells revealed that more than 75% of the 
transcripts belonged to one homologous TCR family including 
the TCRA sequences of clone D  and the CD8 + T cell line. 
Although this pattern of TCR usage contrasts with reports 
of other alloreactive T  cells, conserved TCR. usage was de- 
scribed for a xenogenic response of mice to HLA-Cw3 (41) 
and for antigen specific T  cells. For example, TCR specific 
for influenza peptides presented by HLA class I molecules 
exhibited dominant usage of certain TCRAV and TCRBV 
gene segments and highly homologous CDR3 sequences (42, 
43). Strong evidence exists that the CDR3 interact with pro- 
truded side chains of the antigenic peptide presented by the 
MHC molecule (3, 44,  45).  Accordingly, only one or two 
amino acids of the CDR3,  are critically involved in the in- 
teraction with one of the peptide side chains. The CDR3a 
of these B35-associated TCR all have an isoleucine followed 
by a basic, aliphatic residue and an amino acid with a small 
noncharged side chain; similarly the CDR3B show a stretch 
of three conserved amino acids with glutamic acid followed 
by two glycine residues. These particular arrangements in 
the CDR3 and similar functional patterns support the con- 
tention that these TCR recognize the same or highly related 
peptides and that their specificity can be attributed to CDR3 
sequences in a manner analogous to self MHC-restricted T 
ceils. For these alloreactive T cells the specificity of the TCR 
would appear to result from a direct interaction with a pep- 
tide presented by B35 and not from an indirect conforma- 
tional effect of peptide on the MHC molecule. The role of 
peptide in driving this selection is best exemplified by the 
finding that from an in vivo pool of VA2S3J36 and VB4J2S7 
TCR with rather different CDR3 only those with homolo- 
gous CDR3 were found among the B35-alloreactive T cells. 
The nature of the original stimulus that led to in vivo ex- 
pansion of these particular T cells remains unknown: the donor 
was  not  directly exposed  to  a  B35-associated  allogeneic 
stimulus through transplantation, blood transfusion, or preg- 
nancy. Even stronger clonal expansions of particular CD8 + 
T cells that dominate a given V/3 family were described for 
elderly individuals, but their specificity was not character- 
ized (46). A recent study of Burrows et al. demonstrated that 
the alloresponse to  HLA-B*4402  of HLA-B8,  EBV-sero- 
positive individuals is dominated by CTL that recognize an 
EBNA3-derived peptide presented by HLA-B8; thus a patho- 
gen driven response in vivo can result in a cross-reactive al- 
logeneic response in vitro (47). EBV transformed B cells of 
donor GM were not recognized by the HLA-B35-alloreactive 
T  cells (data not shown), although EBV would provide a 
persistent stimulus in vivo. 
The maintenance of oligoclonally expanded, alloreactive 
T  cell populations over long periods could have important 
implications for transplantation. Acute graft rejection occur- 
ring from one week to several months after transplantation 
is usually considered to be initiated by interactions of T helper 
and CTL; a restricted V/~ usage was shown for alloreactive 
T cell lines established from renal allografts during an active 
phase of rejection (48).  The immunological basis  of accel- 
erated (early acute) graft rejection that occurs within days 
of engraftment is unclear, although it is also thought to be 
cell mediated (49). The prevalence of presensitized CTL that 
mediate alloresponses  against a class I mismatched graft may 
contribute to this practically untreatable form of rejection. 
If preexpanded T cell populations sharing homologous TCIL 
cause early acute allograft rejection it may be possible to de- 
velop strategies to achieve TCR-specific immunosuppression 
similar to those utilized in experimental animal models (50). 
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